Neratinib News and Research

RSS
Simple blood tests can benefit women with breast cancer

Simple blood tests can benefit women with breast cancer

Existing drug used to treat alcoholism is potentially effective against COVID-19

Existing drug used to treat alcoholism is potentially effective against COVID-19

A two-drug combo that halts growth of cancer cells discovered

A two-drug combo that halts growth of cancer cells discovered

Yale scientists build powerful genomic research platform to study cervical cancer

Yale scientists build powerful genomic research platform to study cervical cancer

Drug that treat human breast cancer might also work for canine lung cancer

Drug that treat human breast cancer might also work for canine lung cancer

Two genomic tests help identify most effective treatment for breast cancer patients

Two genomic tests help identify most effective treatment for breast cancer patients

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Tumor's 'microenvironment' plays key role in altering therapeutic response of breast cancer

Tumor's 'microenvironment' plays key role in altering therapeutic response of breast cancer

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Researchers test promising new breast cancer drugs

Researchers test promising new breast cancer drugs

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011